68 results
PRE 14A
SYRS
Syros Pharmaceuticals Inc.
12 Apr 24
Preliminary proxy
4:30pm
salaries and bonuses and grants equity incentive awards to our executive officers. In setting base salaries and bonus targets, our compensation
424B5
SYRS
Syros Pharmaceuticals Inc.
19 Dec 23
Prospectus supplement for primary offering
4:53pm
with Incyte Corporation, or Incyte, will yield any validated targets, whether Incyte will exercise any of its options to exclusively license … intellectual property directed to such targets, and whether and when any of the target validation fees, option exercise fees, milestone payments or royalties
8-K
tm4j vt7oklqv87
11 Aug 23
Termination of a Material Definitive Agreement
4:30pm
424B5
ji1e156mddempab9axx
1 May 23
Prospectus supplement for primary offering
4:06pm
8-K
EX-99.1
xpjey
12 Dec 22
Regulation FD Disclosure
7:48am
425
iisei91xtm9ci 4qw1
2 Sep 22
Business combination disclosure
4:03pm
8-K
j618udrk9jy ot58
2 Sep 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:01pm
424B3
6np2bz0vh65gnwen1z5q
8 Aug 22
Prospectus supplement
5:47pm